Skip to main content
CDC Website

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis).

Read more on Grants.gov
Funding ID:
PAR-22-185
Application Due Date:
Application Contact
Betty
Poon
In Vitro Testing and Screening of HIV compounds
240.669.5024
poonb@niaid.nih.gov
Technical Contact
Brigitte
Sanders
Evaluations in Small Animal Models for HIV, HBV, HCV and MTB
240.627.3209
sandersbe@niaid.nih.gov
  • HIV/AIDS
  • National
  • HIV
  • HIV and AIDS Prevention
Was this page helpful? Give Feedback